Transgenomic reports it has previously signed a contract with OSI Pharmaceuticals to complete an analysis of specific cancer pathway genes
Transgenomic has developed a high throughput, high sensitivity methodology for characterising genetic variants implicated in malignant neoplasia.
Through the development and use of high throughput genome scanning with proprietary endonucleases, forward and reverse Sanger sequencing, and unparalleled variant annotation, Transgenomic says it is unmatched in its reliability to detect pathogenic genetic mutations.
In making the announcement, Transgenomic's president and chief executive officer, Craig Tuttle, stated: "The contract with OSI Pharmaceuticals enables Transgenomic to utilise its highly developed expertise in genetic variant detection to assist OSI Pharmaceuticals in its development efforts.
"This contract follows genetic analysis work done with other pharmaceutical companies.
"It is one of the ways Transgenomic can contribute to the development of therapeutics that benefits patients".
Transgenomic claims unique proprietary expertise that enables highly sensitive detection of cancer causing genetic mutations making it one of the leading laboratories in the USA for this service.
